Please visit answersincme.com/860/97150451-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss treatment strategies for resectable and unresectable disease while highlighting ways to optimize long-term outcomes. Upon completion of this activity, participants should be better able to: Review the implications of the latest evidence evaluating immunotherapy (IO)-based regimens in resectable and unresectable early-stage non-small cell lung cancer (NSCLC); and Integrate patient-centered care into the management of early-stage NSCLC.

Please visit answersincme.com/UNP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in hepatology discusses the latest evidence and guideline recommendations for the first-line treatment of unresectable hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended preferred treatment options for management of unresectable HCC; and Recognize key clinical factors that should be considered when optimizing management for patients with unresectable HCC.

Please visit answersincme.com/860/IME-2025-21131-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in hematology/oncology discuss use of anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM). Upon completion of this activity, participants should be better able to: Identify the rationale for anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM); Evaluate the clinical implications of evidence on anti-CD38 monoclonal antibody–containing quadruplet therapies in patients with NDMM; and Review strategies to optimize anti-CD38 monoclonal antibody–containing quadruplet therapies, including in the community setting.

Please visit answersincme.com/860/MED-ONC-03650-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in the management of squamous non–small-cell lung cancer (NSCLC) discuss guideline-based treatment selection, clinical factors guiding the personalization of immunotherapy plans, and long-term strategies to optimize outcomes in squamous disease. Upon completion of this activity, participants should be better able to: Assess guideline-based recommendations and biomarker profiles to inform first-line immunotherapy-based treatment selection for squamous NSCLC; Identify clinical factors that may be used to tailor first-line immunotherapy-based approaches across a range of PD-L1 expression levels and patient subtypes; and Recommend long-term, real-world clinical approaches to optimize the risk/benefit profiles of immunotherapy-based treatments in patients with squamous NSCLC.

Please visit answersincme.com/860/97150451-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss case-based strategies for integrating perioperative immunotherapy in resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the implications of the latest evidence evaluating immunotherapy (IO)-based regimens in resectable and unresectable early-stage non-small cell lung cancer (NSCLC); and Outline multidisciplinary approaches to optimize perioperative and consolidation IO-based treatment strategies in patients with early-stage NSCLC.

Please visit answersincme.com/XRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses how to optimize the use of adjuvant CDK4/6 inhibitors for managing patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. A patient also shares their experience with adjuvant CDK4/6 inhibitor therapy. Upon completion of this activity, participants should be better able to: Identify patients with hormone receptor–positive, HER2-negative, early breast cancer who are at a high risk of recurrence; Review current guidelines and evidence informing the use of adjuvant CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer; and Outline patient-centered strategies to optimize outcomes with adjuvant CDK4/6 inhibitors in hormone receptor–positive, HER2-negative, high-risk early breast cancer.

Please visit answersincme.com/ZWX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer. Upon completion of this activity, participants should be better able to: Identify the role of TROP2-directed ADCs in the treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer; Review the clinical profiles of TROP2-directed ADCs for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer; and Apply guideline-concordant, evidence-based strategies to incorporate TROP2-directed ADCs into treatment plans for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer.

Please visit answersincme.com/JXV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in metastatic non–small-cell lung cancer discusses how to optimize frontline immunotherapy-based regimens for long-term outcomes. Upon completion of this activity, participants should be better able to: Identify patients with metastatic NSCLC who may benefit from first-line immunotherapy-based regimens; Evaluate the long-term evidence on first-line immunotherapy-based regimens for the treatment of patients with metastatic NSCLC; and Outline evidence-based, patient-centered strategies to ensure optimal use of first-line immunotherapy-based regimens, from initiation to follow-up care after discontinuation, in patients with metastatic NSCLC.

Please visit answersincme.com/BJV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses CD19-directed CAR T-cell therapies in patients with relapsed/refractory large B-cell lymphoma. Upon completion of this activity, participants should be better able to: Review the rationale for CD19-directed CAR T-cell therapies in patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy; Discuss the clinical profiles of available CD19-directed CAR T-cell therapies for patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy; and Outline patient-centered strategies for optimizing treatment with CD19-directed CAR T-cell therapies in patients with R/R LBCL who have early relapse after frontline chemoimmunotherapy.

Please visit answersincme.com/ZMN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the management of non–small-cell lung cancer (NSCLC) discusses first-line treatment of advanced EGFR-mutated NSCLC. Upon completion of this activity, participants should be better able to: Review current guideline recommendations for the first-line treatment of advanced EGFR-mutated NSCLC; Describe the clinical implications of the latest evidence on first-line therapeutic strategies for advanced EGFR-mutated NSCLC; and Outline evidence-based strategies to personalize first-line therapeutic selection for patients with advanced EGFR-mutated NSCLC.

Please visit answersincme.com/860/98336099-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss use of antibody-drug conjugates (ADCs) for patients with hormone-receptor (HR)–positive, HER2-low and -ultralow metastatic breast cancer. Upon completion of this activity, participants should be better able to: Describe the clinical significance of HER2-low and ultralow status in patients with metastatic breast cancer (mBC); Integrate testing strategies for HER2-low and ultralow mBC; Evaluate the clinical data for antibody drug conjugates (ADCs) in HER2-low and ultralow mBC; and Propose practical strategies to enhance the current and future use of ADCs in HER2-low and -ultralow mBC.

Please visit answersincme.com/860/240201301-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss how the latest evidence on frontline immunotherapy-based regimens can be integrated into practice to optimize outcomes for patients with advanced NSCLC. Upon completion of this activity, participants should be better able to: Review the latest data on frontline immunotherapy-based regimens for the treatment of advanced NSCLC; Identify patient-, disease-, and drug-related factors that may inform the frontline use of immunotherapy-based regimens for advanced NSCLC; and Outline evidence-based, multidisciplinary strategies to optimize long-term patient outcomes with frontline immunotherapy-based regimens in advanced NSCLC.

Please visit answersincme.com/99485655-replay860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) use a case-based approach to explore evidence-based strategies to optimize early-stage, resectable NSCLC care with (neo)adjuvant/perioperative immunotherapy, highlighting the role of multidisciplinary teams. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the (neo)adjuvant/perioperative treatment of patients with early-stage, resectable NSCLC; Formulate strategies to appropriately integrate immunotherapy-based (neo)adjuvant/perioperative regimens into treatment plans for patients with early-stage, resectable NSCLC; Discuss multidisciplinary team approaches to enhance care for patients with early-stage, resectable NSCLC.

Please visit answersincme.com/GTM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in sickle cell disease discusses comprehensive therapeutic selection strategies, from disease-modifying therapies to gene therapy options, and evidence-based approaches for optimizing patient outcomes across the disease spectrum. Upon completion of this activity, participants should be better able to: Review the impact that disease manifestations such as vaso-occlusive crises have on patients with sickle cell disease; Assess the efficacy and safety of available therapies for sickle cell disease and their implications for clinical practice; and Apply evidence-based strategies to optimize treatment outcomes in patients with severe sickle cell disease.

Please visit answersincme.com/860/240201294-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in chronic lymphocytic leukemia (CLL) use case examples to discuss how to select and sequence treatments for patients with CLL. Upon completion of this activity, participants should be better able to: Review guideline recommendations for preferred treatments in patients with CLL; Identify the clinical implications of the latest evidence informing the use of second-generation BTK inhibitors in patients with CLL; Outline practical strategies to optimize outcomes with second-generation BTK inhibitors in patients with CLL; and Describe emerging therapeutic agents currently under investigation for the treatment of CLL.

Please visit answersincme.com/FAH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancer discusses strategies to integrate anti-EGFR therapies into the treatment of metastatic colorectal cancer. Upon completion of this activity, participants should be better able to: Describe the clinical significance of the latest evidence for anti-EGFR-based regimens for patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC); Outline strategies to optimize the integration of anti-EGFR-based regimens into management plans for patients with RAS/BRAF wild-type mCRC; and Review guideline recommendations for the management of RAS/BRAF wild-type mCRC.

Please visit answersincme.com/PYP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses TROP2-directed antibody-drug conjugates (ADCs) for the treatment of patients with advanced, pretreated EGFR-mutated NSCLC. Upon completion of this activity, participants should be better able to: Identify the rationale for using TROP2-directed ADCs in the treatment of patients with advanced, pretreated EGFR-mutated NSCLC; Review clinical evidence on emerging TROP2-directed ADCs in patients with advanced, pretreated EGFR-mutated NSCLC; and Outline evidence-based strategies to incorporate TROP2-directed ADCs for patients with advanced, pretreated EGFR-mutated NSCLC.

Please visit answersincme.com/BUS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses the latest treatments for transfusion-dependent beta thalassemia (TDT). Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of the efficacy and safety data for novel TDT therapies; Identify appropriate patients for novel TDT therapies; and Apply strategies to integrate novel TDT therapies into real-world clinical practice.

Please visit answersincme.com/860/27391-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in breast cancer discuss patient-centered strategies to optimize quality of life by implementing a proactive approach to adverse event management for HR+, HER2- mBC. Upon completion of this activity, participants should be better able to: Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations; and Identify proactive, patient-focused strategies to elevate survivorship for patients receiving ADCs for HR+, HER2- mBC.

Please visit answersincme.com/860/27391-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts illustrate how to sequence available therapies for HR+, HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the expert recommendations regarding a sequential approach to the use of ADCs for HR+, HER2- metastatic breast cancer (mBC) management; and Outline evidence-based clinical strategies to enhance a sequential therapeutic approach in real-world patient populations.